These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22228356)
1. F-18 FDG and C-11 methionine PET/CT in intracranial dural metastases. D'Souza MM; Jaimini A; Tripathi M; Garg N; Sharma R; Monndal A; Tripathi RP Clin Nucl Med; 2012 Feb; 37(2):206-9. PubMed ID: 22228356 [TBL] [Abstract][Full Text] [Related]
2. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors. Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339 [TBL] [Abstract][Full Text] [Related]
3. Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Bochev P; Klisarova A; Kaprelyan A; Chaushev B; Dancheva Z Hell J Nucl Med; 2012; 15(2):125-9. PubMed ID: 22741148 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912 [TBL] [Abstract][Full Text] [Related]
5. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Li DL; Xu YK; Wang QS; Wu HB; Li HS Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
7. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Kitajima K; Nakamoto Y; Okizuka H; Onishi Y; Senda M; Suganuma N; Sugimura K Ann Nucl Med; 2008 Aug; 22(7):595-602. PubMed ID: 18756362 [TBL] [Abstract][Full Text] [Related]
8. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study. Manohar K; Bhattacharya A; Mittal BR Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001 [TBL] [Abstract][Full Text] [Related]
10. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771 [TBL] [Abstract][Full Text] [Related]
12. Is a selective brain (18)F-FDG PET/CT study profitable in patients with small cell lung cancer? Palomar Muñoz A; García Vicente AM; Bellón Guardia ME; González García B; Talavera Rubio MP; Pilkington Woll JP; Núñez García A; Poblete García VM; Cordero García JM; Soriano Castrejón A Rev Esp Med Nucl Imagen Mol; 2012; 31(3):124-9. PubMed ID: 21722995 [TBL] [Abstract][Full Text] [Related]
13. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan. Trybek T; Kowalska A; Lesiak J; Młynarczyk J Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108 [TBL] [Abstract][Full Text] [Related]
14. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging]. Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892 [TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086 [TBL] [Abstract][Full Text] [Related]
16. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509 [TBL] [Abstract][Full Text] [Related]
17. F-18 fluorodeoxyglucose PET/CT and post hoc PET/MRI in a case of primary meningeal melanomatosis. Lee HJ; Ahn BC; Hwang SW; Cho SK; Kim HW; Lee SW; Hwang JH; Lee J Korean J Radiol; 2013; 14(2):343-9. PubMed ID: 23483049 [TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT in a Case of Dural Amyloidoma. Ran P; Liu Y; Liang X; Zhang Y; Dong A Clin Nucl Med; 2018 Dec; 43(12):925-929. PubMed ID: 30300204 [TBL] [Abstract][Full Text] [Related]
19. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities. Salem SS; Shahin MA Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387 [TBL] [Abstract][Full Text] [Related]
20. A case of primary leptomeningeal melanoma evaluated on FDG PET/CT. Golden MJ; Wheir WH; Katzman J; Turk ZA; Hartshorne MF Clin Nucl Med; 2011 Oct; 36(10):919-21. PubMed ID: 21892047 [No Abstract] [Full Text] [Related] [Next] [New Search]